assume the news may leak, in which case I would expect TA to give some leading indication of the forthcoming good news.
Hi,Peter
I know you are a non-believer in TA.<g>
Re: REGN, from a TA standpoint, it is on a down-trend on its monthly, weekly and daily charts.<g>
On its daily chart, the downtrend that started on Jan.4 from the $3.07level is intact and the stock at present needs to close above $2.87 in order to break the downtrend.
bigcharts.marketwatch.com
On its weekly chart, the downtrend started on Sep.19 2003 at the $8.29 level and the stock needs to close above $3.50
bigcharts.marketwatch.com
On the monthly chart, the downtrend coming from its March 2000 H at $18 was broken at $4.25 on March 28,2002 and the stock rallied to $8.47 on Sep.30 2003 when the downtrend started again.(It needs to close above $4.80 to break it.<g>)
bigcharts.marketwatch.com
As you said, there doesn't seem to be much expectation that the results of their secretin, or RG1068, in schizophrenic patients will show good results. I think they also have a trial going on evaluating Uridine for neurological disorders, and CTLA4-Ig their a monoclonal antibody,for R.A. and other autoimmune diseases.
Their patent on CTLA4-IG which they licensed from the Univ. of Michigan. You, as a lawyer, know a lot more about the rightful claim of ownership of the patent in question.
I thought that BMY claims that Dr.Craig Thompson from the U.M., collaborated with BMY scientists and that he is a rightful inventor on patents that were issued to BMY.
I also thought that the Distric Court in Sep.2003 found that RGEN and the Univ. of Michigan were not sole or joint owners of the patent in question and that RGEN had appealed to the U.S. Court of the Federal Circuit with the final decision still pending.
At any rate, if RGEN's volume starts picking up to the upside or it gets off its present downtrend, I will try to let you know.<g>
RAGL
Bernard |
